NCT06424717尚未招募2 期
A Single Arm, Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Avelumab in Combination With the ATR Inhibitor Tuvusertib in Participants With Advanced Urothelial Carcinoma That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 70
- 主要终点
- Confirmed Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors(RECIST) v1.1 as Assessed by Investigator in Participants with Selected Tumor Chromatin Modifier Mutations
研究概览
简要总结
The purpose of this study is to assess the antitumor activity of avelumab in combination with tuvusertib in terms of objective response in participants with advanced urothelial carcinoma. Study details include:
Condition/Disease: Participants with urothelial carcinoma (locally advanced and unresectable, or metastatic) that has progressed on prior anti-PD-(L)1 therapy Treatment Duration: Participants will be treated until progressive disease, death, or discontinuation due to e.g. withdrawal of consent or lost to follow-up Visit Frequency: While receiving study intervention, participants will visit the site twice per every 21-day study intervention period. 1 week after end of study intervention, participants will visit the site for an End of Study Intervention Visit, followed by 2 Safety Follow-Up visits at 1 and 3 months after last dose, and thereafter have remote Long-Term Follow-up every 3 months.
Study Duration: The overall study is planned to close after the last participant has been followed up for at least 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed, locally advanced, and unresectable or metastatic urothelial carcinoma.
- •No more than 2 lines of therapy for advanced disease. Chemotherapy followed by avelumab (switch maintenance) counts as 1 line of therapy. Additionally, (neo)-adjuvant chemotherapy for Muscle invasive bladder cancer with recurrence or progression within 12 months of last dose, counts as a line of therapy.
- •Measurable disease by RECIST 1.1, as assessed by the Investigator.
- •Eastern Cooperative Oncology Group Performance status 0 to
- •Adequate hematologic function as indicated by:
- •Platelet count more than or equal to 100,000 per microliter
- •Absolute neutrophil count more than or equal to 1,500 per microliter with no growth factor treatment within the last 14 days
- •Hemoglobin more than or equal to 9.0 gram/deciliter with no erythropoietin or red blood cell transfusion within the last 14 days
- •Only one line of an antibody-drug conjugate (ADC) is allowed.
- •Other protocol defined inclusion criteria could apply.
排除标准
- •Any condition, including any uncontrolled disease state other than aUC, that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
- •Any known additional malignancy that is progressing and/or requires active treatment including adjuvant hormonal therapy.
- •Presence of brain metastases unless clinically stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of study intervention and any neurologic symptoms have returned to baseline and sequelae that are a consequence of the treatment of the brain metastases are acceptable), no evidence of new brain metastases, and on a stable or decreasing dose or without steroids for at least 14 days prior to first dose of study intervention. Participants with carcinomatous meningitis are excluded regardless of clinical stability.
- •Serious gastrointestinal bleeding within 3 months, refractory nausea and vomiting, uncontrolled diarrhea, known malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes, other chronic gastrointestinal disease (including exocrine pancreatic insufficiency requiring pancreatic enzyme replacement therapy), and/or other situations that may preclude adequate absorption of oral medications.
- •Other protocol defined exclusion criteria could apply.
研究组 & 干预措施
Avelumab with tuvusertib
Experimental
干预措施: Avelumab (Drug)
Avelumab with tuvusertib
Experimental
干预措施: Tuvusertib (Drug)
结局指标
主要结局
Confirmed Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors(RECIST) v1.1 as Assessed by Investigator in Participants with Selected Tumor Chromatin Modifier Mutations
时间窗: Up to 18 months
次要结局
- Confirmed Objective Response (OR) According to RECIST v1.1 as Assessed by Investigator(Up to 18 months)
- Duration of Response (DoR) According to RECIST 1.1 as Assessed by the Investigator(Up to 18 months)
- Progression Free Survival (PFS) According to RECIST 1.1 as Assessed by the Investigator(Up to 18 months)
- Overall Survival (OS)(From the date of randomization until death, assessed up to 1.5 years)
- Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs and Related TEAEs(Up to 18 months)
- Confirmed Objective Response (OR) According to RECIST v1.1 as Assessed by Investigator in Subpopulations as Defined by Selected Tumor Biomarkers(Up to 18 months)
- Duration of Response (DoR) According to RECIST 1.1 as Assessed by the Investigator in Subpopulations as Defined by Selected Tumor Biomarkers(Up to 18 months)
- Progression Free Survival (PFS) According to RECIST 1.1 as Assessed by the Investigator in Subpopulations as Defined by Selected Tumor Biomarkers(Up to 18 months)
- Overall Survival (OS) in Subpopulations as Defined by Selected Tumor Biomarkers(From the date of randomization until death, assessed up to 1.5 years)
研究者
相似试验
进行中（未招募）
2 期
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Locally Advanced or Metastatic Urothelial CarcinomaNCT05327530EMD Serono Research & Development Institute, Inc.256
已完成
1 期
A Combination of Avelumab and Taxane (AVETAX) for Urothelial CancerUrothelial CarcinomaNCT03575013Yousef Zakharia21
终止
1 期
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)Non-Small Cell Lung CancerNCT02584634Pfizer43
进行中（未招募）
2 期
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialClinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Locally Advanced Merkel Cell CarcinomaMetastatic Merkel Cell CarcinomaRefractory Merkel Cell CarcinomaUnresectable Merkel Cell CarcinomaNCT05947500National Cancer Institute (NCI)50
已完成
2 期
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard TherapyGastrointestinal Stromal TumorsNCT04258956Maria Sklodowska-Curie National Research Institute of Oncology58